ArticleJournal of the peripheral nervous system : JPNS2022
Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands.
Article in Journal of the peripheral nervous system : JPNS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Brazilian Academy of Neurology recommendations for diagnosis, management, and treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).Arquivos de neuro-psiquiatria · 2025Guideline
- A Practical Guide to Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.Neurology and therapy · 2026Review
- Maintenance intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: trends from an Australian tertiary centre.Internal medicine journal · 2026Observational
- Therapeutic Plasma Exchange in the Elderly: Rare Indications but Good Tolerability.Journal of clinical apheresis · 2026Article
- Incidence, Prevalence, and Treatment Patterns in Chronic Inflammatory Demyelinating Polyneuropathy: Data Analysis of US Claims.Neuroepidemiology · 2026Article
- Immunotherapy in Chronic Inflammatory Demyelinating Polyneuropathy and the Emerging Role of Efgartigimod.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Autoimmune Neuromuscular Disorders at a Molecular Crossroad: Linking Pathogenesis to Targeted Immunotherapy.International journal of molecular sciences · 2025Review
- Epidemiology, Presentation, Management and Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy in Birmingham, UK: The Impact of Ethnicity.Journal of the peripheral nervous system : JPNS · 2025Article
- Prevalence and incidence rates of 17 neuromuscular disorders: An updated review of the literature.Journal of neuromuscular diseases · 2025Review
- The journey to diagnosis for patients with CIDP: results from a real-world international survey.Frontiers in neurology · 2025Article
- Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy.European journal of neurology · 2024Article
- Progressive demyelinating polyneuropathy after hematopoietic cell transplantation in metachromatic leukodystrophy: a case series.Journal of neurology · 2024Article
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Current Therapeutic Approaches and Future Outlooks.ImmunoTargets and therapy · 2024Review
- Analysis of Post-COVID-19 Guillain-Barré Syndrome over a Period of One Year in the University Hospital of Split (Croatia).Neurology international · 2023Article
- Epidemiology of Chronic Inflammatory Demyelinating Polyneuropathy in South Korea: A Population-Based Study.Journal of clinical neurology (Seoul, Korea) · 2023Article
- Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands.Journal of the peripheral nervous system : JPNS · 2022Article
- Sex differences in Guillain Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy and experimental autoimmune neuritis.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare but disabling disorder that often requires long-term immunomodulatory treatment. Background incidence rates and prevalence and risk factors for developing CIDP are still poorly defined. In the current study, we used a longitudinal population-based cohort study in The Netherlands to assess these rates and demographic factors and comorbidity associated with CIDP. We determined the incidence rate and prevalence of CIDP between 2008 and 2017 and the occurrence of potential risk factors in a retrospective Dutch cohort study using the Integrated Primary Care Information (IPCI) database. Cases were defined as CIDP if the diagnosis of CIDP was described in the electronic medical file. In a source population of 928 030 persons with a contributing follow-up of 3 525 686 person-years, we identified 65 patients diagnosed with CIDP. The overall incidence rate was 0.68 per 100 000 person-years (95% CI 0.45-0.99). The overall prevalence was 7.00 per 100 000 individuals (95% CI 5.41-8.93). The overall incidence rate was higher in men compared to woman (IRR 3.00, 95% CI 1.27-7.11), and higher in elderly of 50 years or older compared with people <50 years of age (IRR 17 95% CI 4-73). Twenty percent of CIDP cases had DM and 9% a co-existing other auto-immune disease. These background rates are important to monitor changes in the frequency of CIDP following infectious disease outbreaks, identify potential risk factors, and to estimate the social and economic burden of CIDP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.